One-year data confirm efficacy of Kuros' KUR-111 in fractures
This article was originally published in Scrip
Executive Summary
Kuros Biosurgery, a Swiss biotech company developing biomaterials and bioactive-biomaterial combinations for trauma, wound and spinal indications, has released one-year follow-up data from a Phase IIb trial that confirm the efficacy of KUR-111, a composite product for tibial plateau fractures.